Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have Crohn's disease of at least 3 months' duration with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, or endoscopy~* Have active Crohn's disease, defined as a baseline Crohn's Disease Activity Index (CDAI) score of \>= 220 and \<= 450~* Have received infliximab, adalimumab, or certolizumab pegol at a dose approved for the treatment of Crohn disease and did not respond initially (ie, primary nonresponse)~* Or responded initially but then lost response with continued therapy (ie, secondary nonresponse)~* Or were intolerant to the medication~* Have screening laboratory test results within protocol-specified parameters.~Exclusion Criteria:~* Patients who have had any kind of bowel resection within 6 months~* Are pregnant or planning pregnancy (both men and women) while enrolled in the study or for 20 weeks after receiving study agent~* Patients who have received infliximab, adalimumab or certolizumab pegol \< = 8 weeks before the first administration of study drug~* Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug~* Patients with a history of or ongoing chronic or recurrent infectious disease~* Patients who have previously received a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: PLACEBO_COMPARATOR): Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
- 002 (Type: EXPERIMENTAL): Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
- 003 (Type: EXPERIMENTAL): Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg) 390 mg (weight \> 55 kg and \<= 85 kg) and 520 mg (weight \> 85 kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).